This is a prospective, single-center, open, historically controlled real-world study.

The aims of this study is to evaluate the safety and effectiveness of Nab-paclitaxel combined with oxaliplatin and S-1 in the treatment of patients with advanced gastric cancer.

Inclusion Criteria:

• Gastric adenocarcinoma diagnosed by histology.

• Ambulatory cases, 18-75 years old

• ECOG performance status ≤ 1

• Have not received anti-tumor therapy previously (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy)

• Patients able to tolerate abdominal surgery above grade 3

• Has adequate organ function as defined by the following criteria:

  • WBC> 4.0×10^9/L
  • ANC> 1.5×10^9/L
  • ANC ≥ 1.5×10^9/L
  • HB ≥ 80 g/L
  • PLT ≥ 100×10^9/L
  • TBIL ≤ 1.5×ULN
  • ALT and AST <2.5 × ULN, for patients with liver metastases, ALT and AST <5 × ULN
  • BUN and Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min

• No history of other tumors

• Be willing and able to comply with the plan during the research period

• Has given written informed consent

• Life expectancy ≥ 6 months

Exclusion Criteria:

• Those with a history of other malignancies in the last 5 years, except for cured non-melanoma skin cancer and cervical carcinoma in situ
• HER-2+ and willing to receive Trastuzumab
• Pregnancy or breast-feeding women; Men and women who are sexually active (possible to have children) and unwilling to use contraception during the study period
• Severe, uncontrolled medical diseases and infections; chronic bowel disease or short bowel syndrome
• Major organ failure, such as compensatory cardiopulmonary liver and kidney failure; severe liver and kidney metabolism abnormalities, affecting the normal metabolism of drugs
• Patients with other surgical contraindications, such as serious diseases that are difficult to control
• The researcher believes that patients with a clear gastrointestinal bleeding tendency and/or patients with abnormal blood coagulation function (INR > 1.5)
• Active HBV or HCV
• Peripheral neuropathy ≥ Grade 2 according to NCT-CTC AE5.0
• Patients who are allergic to the drugs in this study, or determined by the investigator as unsuitable to participate in this clinical study